Brenton Ahrens
General Partner at Canaan Partners @ Durata Therapeutics
Menlo Park, United States
Brenton Ahrens is a Series B investor at Durata Therapeutics in Menlo Park focused on Biotechnology and Health Care. Brent Ahrens is the Board of Directors of Abvance Therapeutics. General Partner at Canaan Partners.
- Total investments:
- 33
- Last investment:
- Lead investor:
- 15%
Last updated:
For AI agents: llms.txt
Industries Brenton Ahrens invests in
Stages Brenton Ahrens invests in
Countries Brenton Ahrens invests in
Investment Focus
Industry
- Biotechnology 10 (30%)
- Health Care 8 (24%)
- Medical Device 7 (21%)
- Medical 5 (15%)
- Manufacturing 4 (12%)
Stage
- Series B 5 (15%)
- Funding Round 5 (15%)
- Series A 4 (12%)
- Series D 4 (12%)
- Series C 2 (6%)
Country
- United States 12 (36%)
- United Kingdom 3 (9%)
- Ireland 1 (3%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
ThirtyFiveBio
|
ThirtyFiveBio is a biotechnology agency | Venture - Series Unknown / Apr 15, 2025 | |
Greywolf Therapeutics
|
Grey Wolf Therapeutics is a UK-based drug discovery biotechnology company focused on immuno-oncology. Rather than targeting the immune system, Grey Wolf’s approach is to directly alter the tumour cells, illuminating them for attack and destruction by the immune system. THey are targeting the endoplasmic reticulum aminopeptidases (ERAP) 1 and 2 inthe antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells, thus dramatically increasing tumour visibility and extending the reach of immunotherapy in oncology. Grey Wolf is working with leading academic and commercial drug discovery partners to deliver a clinical candidate against a strongly validated target. | $50M / Series B / May 23, 2024 | |
Pathios Therapeutics
|
Pathios Therapeutics is a biotech company focused on the development of therapies for autoimmune diseases and cancer. | $25M / Series B / Apr 18, 2024 | |
illumicell AI
|
illumicell AI combines patented AI algorithms and proprietary microscopy technology to test 50x faster, 20x more effectively, empowering every healthcare provider at the point of care – not just fertility clinics – with accessible, scalable fertility diagnostics. | $300K / Pre-Seed / Oct 09, 2023 | |
Relievant Medsystems
|
Relievant's mission is to provide patients with low risk therapy that can alleviate their back pain. | $50M / Series G / Mar 27, 2023 | |
|
Greywolf Therapeutics
|
Grey Wolf Therapeutics is a UK-based drug discovery biotechnology company focused on immuno-oncology. Rather than targeting the immune system, Grey Wolf’s approach is to directly alter the tumour cells, illuminating them for attack and destruction by the immune system. THey are targeting the endoplasmic reticulum aminopeptidases (ERAP) 1 and 2 inthe antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells, thus dramatically increasing tumour visibility and extending the reach of immunotherapy in oncology. Grey Wolf is working with leading academic and commercial drug discovery partners to deliver a clinical candidate against a strongly validated target. | $49.2M / Series B / Jan 26, 2023 | |
|
Relievant Medsystems
|
Relievant's mission is to provide patients with low risk therapy that can alleviate their back pain. | $70M / Oct 29, 2020 | |
|
Relievant Medsystems
|
Relievant's mission is to provide patients with low risk therapy that can alleviate their back pain. | $70M / Series F / Oct 29, 2020 | |
|
Greywolf Therapeutics
|
Grey Wolf Therapeutics is a UK-based drug discovery biotechnology company focused on immuno-oncology. Rather than targeting the immune system, Grey Wolf’s approach is to directly alter the tumour cells, illuminating them for attack and destruction by the immune system. THey are targeting the endoplasmic reticulum aminopeptidases (ERAP) 1 and 2 inthe antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells, thus dramatically increasing tumour visibility and extending the reach of immunotherapy in oncology. Grey Wolf is working with leading academic and commercial drug discovery partners to deliver a clinical candidate against a strongly validated target. | $3.3M / Series A / Jan 09, 2020 | |
|
Greywolf Therapeutics
|
Grey Wolf Therapeutics is a UK-based drug discovery biotechnology company focused on immuno-oncology. Rather than targeting the immune system, Grey Wolf’s approach is to directly alter the tumour cells, illuminating them for attack and destruction by the immune system. THey are targeting the endoplasmic reticulum aminopeptidases (ERAP) 1 and 2 inthe antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells, thus dramatically increasing tumour visibility and extending the reach of immunotherapy in oncology. Grey Wolf is working with leading academic and commercial drug discovery partners to deliver a clinical candidate against a strongly validated target. | $12.7M / Series A / Feb 11, 2019 | |
| See all 33 investments → | |||
Co-Investors
About Durata Therapeutics
Durata Therapeutics Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Brenton Ahrens
General Partner at Canaan Partners
|
|||
4 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Brenton Ahrens invest in?
Brenton Ahrens invests primarily in Biotechnology, Health Care and Medical Device startups, most often at Series B and Funding Round stage. Most of the 33 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Brenton Ahrens last invest?
The most recent investment recorded for Brenton Ahrens closed in Apr 2025. Shizune tracks 33 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
